April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Oscar Tahuahua: Neoadjuvant Aumolertinib in stage III EGFR+ NSCLC
Apr 6, 2025, 13:40

Oscar Tahuahua: Neoadjuvant Aumolertinib in stage III EGFR+ NSCLC

Oscar Tahuahua, Medical Oncology fellow at National Institute of Cancerology, shared a post on X:

Neoadjuvant Aumolertinib in stage III EGFR+ NSCLC: Ph2 trial
110 mg QD for 16 weeks
ORR: 70.6%
Surgery: 45.1% | R0: 100%
MPR: 21.7% | pCR: 13%
Ex19-Del vs L858R → ORR: 91 vs 59%, MPR: 44 vs 7%
Promising neoadj strategy, esp. in Ex19Del tumors.”